International Cytokine & Interferon Society

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Retrieved on: 
Wednesday, October 11, 2023
Doctor of Philosophy, SOC, Management of prostate cancer, Vaccine, Interleukin 10, Gamma ray, Trial of the century, Cell, Toxicity, Interleukin 12, Infection, International Cytokine & Interferon Society, Safety, National Cancer Institute, Early Prostate Cancer (clinical programme), Interim, Administration, Interleukin, TTY, Cytokine, Docetaxel, DLT, CD8, Head, Research, Clinical trial, Fourth grade, PSA, Bangladesh Technical Education Board, PDSB, Prostate cancer, Biotechnology, CD4, Patient, MD

Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.

Key Points: 
  • Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.
  • Data to be presented by National Cancer Institute as an oral presentation at Cytokines 2023.
  • While all doses of PDS0301 were well-tolerated, the 12.0 mcg/kg dose of PDS0301 with chemotherapy provided the best combination of immune response and tolerability.
  • Interim data highlights to be presented at Cytokines 2023 include:
    All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

Retrieved on: 
Monday, July 17, 2023
Vaccine, Docetaxel, Biotechnology, Prostate cancer, PDSB, Metastasis, Head, Infection, Clinical trial, Bangladesh Technical Education Board, National Cancer Institute, Cytokine, Early Prostate Cancer (clinical programme), TTY, Patient, International Cytokine & Interferon Society, Cancer, NCI, Safety, Medical imaging, Immunotherapy

The abstract, titled, “Combining an IL-12-based Immunocytokine (PDS0301) with Docetaxel in Metastatic Prostate Cancer: Preliminary Safety and Immune Data”, will report interim safety and immune data on 18 patients in the clinical trial being led by the National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • The abstract, titled, “Combining an IL-12-based Immunocytokine (PDS0301) with Docetaxel in Metastatic Prostate Cancer: Preliminary Safety and Immune Data”, will report interim safety and immune data on 18 patients in the clinical trial being led by the National Cancer Institute (NCI), part of the National Institutes of Health.
  • The trial is investigating the safety, immune responses and clinical activity of PDS0301 and docetaxel in metastatic castration-sensitive and castration-resistant prostate cancer patients.
  • The study is designed to evaluate three dose levels of PDS0301 (8 mcg/kg, 12 mcg/kg, and 16.8 mcg/kg) in combination with docetaxel (75 mg/m2) administered every three weeks.
  • “This clinical trial provides an important opportunity to investigate the potential of PDS0301 combined with docetaxel chemotherapy to offer improved treatment options for patients with metastatic castration-sensitive and castration-resistant forms of prostate cancer.

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, June 27, 2023
GMP, Patent, Society, D, Neuro-Oncology (journal), Oppenheimer, Calendar, Food and Drug Administration, Clinical trial, Cancer, Skin, Immunotherapy, Research, MDNA, EDGAR, Glioblastoma, Colon, Net, HIV disease progression rates, Patient, United States Patent and Trademark Office, International Cytokine & Interferon Society, SEDAR, Merck, Pembrolizumab, IND, SD, Tumor microenvironment, Food, Safety, Breast cancer, Vaccine, Cryptocurrency, Pharmaceutical industry, Rare-earth element

Program highlights for the fiscal year ended March 31, 2023, along with recent developments, include:

Key Points: 
  • Program highlights for the fiscal year ended March 31, 2023, along with recent developments, include:
    In March 2023, Medicenna provided its most recent update on the MDNA11 clinical development program.
  • In January 2023, topline results from the single-arm Phase 2b clinical trial of MDNA55 were published in the peer reviewed journal, Neuro-Oncology.
  • In April 2023, Medicenna presented preclinical data characterizing IL-13 Superkines and next-generation Superkines at the 2023 Annual Meeting of the American Association for Cancer Research.
  • In February 2023, Medicenna established an at-the-market offering facility with Oppenheimer & Co. Inc. whereby, Medicenna may sell common shares with an aggregate offering price of up to US$10 million.

Senda Biosciences Appoints Luke O’Neill, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 12, 2023
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Az-Zubair Prize for Innovation and Scientific Excellence, Flagship Pioneering, Royal Society, Doctor of Philosophy, Royal Dublin Society, Pharmacology, United States Air Force Scientific Advisory Board, Royal, International Cytokine & Interferon Society, Trinity College Dublin, Inflammation, Trinity College, CSO, Biochemistry, Research, Receptor (biochemistry), Federalisation of the European Union, Macrophage, Immunology, Inflammasome, Management

Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
  • “Luke is a key addition to what is already a strong, effective leadership team,” said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.
  • “Luke is a world-renowned immunologist who has contributed so much to the organization in his corporate governance and scientific advisory roles.
  • He holds a Ph.D. in pharmacology from the University of London and conducted postdoctoral research at the University of Cambridge, UK.

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 4, 2022
MSD, Patient, EMA, FDA, Population, MD, United States patent law, Research, Cytokine, Annual report, Patent, Melanoma, SD, SITC, Company, CD122, GLOBE, Intellectual property, IND, NK, Toxic leukoencephalopathy, Immunotherapy, CEO, Renal cell carcinoma, Mission statement, Forward-looking statement, ID, PD, Society, Pharmacokinetics, EDGAR, Doctor of Philosophy, Method, 1836 U.S. Patent Office fire, MDNA, Annual general meeting, Biskit, Pancreatic cancer, International Cytokine & Interferon Society, Safety, GBM, CD25, Brain, Merck & Co., PR, USD, NASDAQ, IP, Pembrolizumab, United, News, SEDAR, GMP, Leukemia, Bifunctional, Mobile phone, Pharmaceutical industry, Vaccine, Security (finance), Cryptocurrency, Audit, Merck

TORONTO and HOUSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2022. All dollar amounts are in Canadian currency unless otherwise noted.

Key Points: 
  • The confirmatory scan for this patient showed further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy.
  • All patients in the trials dose escalation phase are treated with MDNA11 monotherapy via intravenous infusion every two weeks.
  • Under the terms of the agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA.
  • Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Annual report, Large-cell lung carcinoma, Structural biology, Cytokine, Radiation, Inflammation, RCC, Partnership, GLOBE, Research, HCC, CD73, ICIS, Antibody, Renal cell carcinoma, COVID-19, Program, Gene expression, Risk, IND, R, U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, G&A, Workforce, Adenocarcinoma, IL-27, International Cytokine & Interferon Society, Private Securities Litigation Reform Act, Novartis, Surface, Investor relations, Investigational New Drug, FDA, Inflammation Research, CD39, Tumor microenvironment, Patient, Food, Webcast, PVRIG, ORR, Unit, Forward-looking statement, CCR8, GlaxoSmithKline, Cell Reports, Pharmaceutical industry, Risk management, Vaccine, NSCLC

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today provided a corporate update and reported financial results for the third quarter of 2022.

Key Points: 
  • We are excited by the monotherapy activity seen with SRF388 in relapsed non-small cell lung cancer (NSCLC), an area of high unmet need globally, said Rob Ross, M.D., chief executive officer.
  • Based on these promising results in relapsed NSCLC, we have opened the second stage of our trial investigating SRF388 as a monotherapy, and we have treated our first patients in a new cohort to investigate SRF388 in combination with pembrolizumab in second to fourth line NSCLC.
  • Based on these results, Surface has opened the second stage of the Simons 2-stage trial which is expected to enroll 40 patients with NSCLC in total.
  • Management now projects that current cash and cash equivalents are sufficient to fund Surface into the second quarter of 2024.

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

Retrieved on: 
Thursday, September 22, 2022
Half-life, P69, Biskit, Type, CD25, FDA, Bifunctional, Cancer, Company, Macrophage, Neoplasm, GBM, CD122, Melanoma, News, Cytokine, Forward-looking statement, Program, Type 2, Tams, NK, Colon, International Cytokine & Interferon Society, Breast cancer, Growth, CEO, TF-1, Serum, Doctor of Philosophy, TME, MDNA, NASDAQ, Immunotherapy, MDSC, GLOBE, Skin, Brain, EMA, Vaccine, Pharmaceutical industry, Online shopping, FC

TORONTO and HOUSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced presentation of data from two preclinical programs that demonstrate the anti-tumor activity of the Company’s anti-PD1-IL-2 (aka MDNA223) BiSKIT (Bi-functional SuperKines for ImmunoTherapy) and long-acting IL-4/IL-13 super-antagonist (aka MDNA413). The data are featured in two separate poster presentations at the 10th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2022), which is taking place both virtually and in-person at the Hilton Waikoloa Village, in Big Island, Hawaii.

Key Points: 
  • In addition, data on our long-acting MDNA413 Superkine demonstrated its potential to reverse the immunosuppressive tumor microenvironment that are known to limit the efficacy of cancer immunotherapies.
  • Poster P110 includes preclinical data from in vitro and in vivo studies of MDNA223, a next generation BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
  • In vivo murine data showed MDNA223 exhibiting a prolonged pharmacodynamic response extending beyond the duration of pharmacokinetic exposure.
  • Poster P69 includes preclinical data from in vitro and in vivo studies of Fc-MDNA413, a novel, long-acting IL-4/IL-13 Superkine.

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Retrieved on: 
Wednesday, September 14, 2022
IL-27, International Cytokine & Interferon Society, The Cancer Genome Atlas, FDA, EDT, TIGIT, Neoplasm, Gene, Poster, ICIS, CD73, Surface, Cytokine, GlaxoSmithKline, Patient, PVRIG, Novartis, Radiation, IFN, Orphan drug, Fast Track, Liver, CD39, Tumor microenvironment, PD-L1, GLOBE, TCGA, Gene expression, Kidney, Type 1, CCR8, Vaccine, Palladium, Pharmaceutical industry, Cancer

CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will present new preclinical data on the role of IL-27 in therapy resistance at the 10th Annual Cytokines Meeting of the International Cytokine and Interferon Society (ICIS) being held September 20 – 23 at Big Island, Hawaii. The poster, entitled IL-27 Inhibits Immune Cell Reinvigoration Mediated by PD-(L)1 Blockade and Induces a Type 1 Interferon Gene Expression Signature Associated with Resistance to Therapy in Cancer Patients (#297), will first be presented in a virtual preview session today at 2:00 - 3:30 pm HST/8:00 - 9:30 pm EDT.

Key Points: 
  • We have identified an IL-27 gene signature that is enriched in several tumor types from The Cancer Genome Atlas (TCGA).
  • Interestingly, this IL-27 signature includes many interferon (IFN) stimulated genes that have been associated with resistance to therapy across different cancers.
  • These findings further bolster our belief that SRF388, a first-in-class anti-IL-27 monoclonal antibody, holds important potential in the treatment of certain cancers.
  • Furthermore, Surface Oncology has identified a potential biomarker associated with IL-27 that may be useful in helping to identify patients most likely to respond to SRF388.

Humanigen Announces Participation and Presentation at Multiple Conferences in October

Retrieved on: 
Tuesday, October 5, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Social media, Veterinary medicine, Chemokine, Goal, Sachs, School, Risk, Granulocyte-macrophage colony-stimulating factor, Health, Cytokine, Webcast, Patient, Central European Time, International Cytokine & Interferon Society, MD, Associate, LinkedIn, Graft-versus-host disease, Twitter, CEO, Chief executive officer, University, ICIS, Knowledge, Healthcare Convention and Exhibitors Association, Mindy, Disease, GM, Judgement, GM-CSF, Forward-looking statement, Nasdaq, CET, SEC, Rheumatoid arthritis, Pharmaceutical industry

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that management will present and participate at multiple virtual investor conferences in October 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that management will present and participate at multiple virtual investor conferences in October 2021.
  • Details of the conferences are as follows:
    Dale Chappell, MD, Chief Scientific Officer, will participate in a fireside chat at 9:00am EDT on October 5, 2021.
  • Sachs and Associates plans to share a video of the panel via its social media networks 1-2 weeks after the event.
  • Humanigen will participate in this combination virtual and in-person event on October 12, 2021.